Paracrine cellular senescence exacerbates biliary injury and impairs regeneration

Sofia Ferreira-Gonzalez1, Wei-Yu Lu1, Alexander Raven1, Benjamin Dwyer1, Tak Yung Man1, Eoghan O’Duibhir1, Philip J. Starkey Lewis1, Lara Campana1, Tim J. Kendall2, Thomas G. Bird1,2,3, Nuria Tarrats4, Juan-Carlos Acosta4, Luke Boulter5 & Stuart J. Forbes1

Cellular senescence is a mechanism that provides an irreversible barrier to cell cycle progression to prevent undesired proliferation. However, under pathological circumstances, senescence can adversely affect organ function, viability and regeneration. We have developed a mouse model of biliary senescence, based on the conditional deletion of Mdm2 in bile ducts under the control of the Krt19 promoter, that exhibits features of biliary disease. Here we report that senescent cholangiocytes induce profound alterations in the cellular and signalling microenvironment, with recruitment of myofibroblasts and macrophages causing collagen deposition, TGFβ production and induction of senescence in surrounding cholangiocytes and hepatocytes. Finally, we study how inhibition of TGFβ-signalling disrupts the transmission of senescence and restores liver function. We identify cellular senescence as a detrimental mechanism in the development of biliary injury. Our results identify TGFβ as a potential therapeutic target to limit senescence-dependent aggravation in human cholangiopathies.
primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are the most prevalent type of cholangiopathies, a diverse group of genetic and acquired disorders that affect the biliary population of the liver. PSC/PBC have variable prognoses but frequently evolve into end-stage liver disease, with limited treatment options.

The aetiologies remain unclear, although a role of cellular senescence in the development of PSC/PBC has been suggested. Senescence is an irreversible cell cycle arrest, driven by dominant cell-cycle inhibitors and characterized by changes in morphology, increased lysosomal content, expression of DNA damage response (DDR) factors, and the activation of the senescence-associated secretory phenotype (SASP).

The SASP is a pro-inflammatory response that activates and reinforces the senescent phenotype in the surrounding cells, modulates fibrosis, and promotes regeneration. The SASP is composed by a variable set of secreted cytokines and chemokines, responsible for the beneficial and deleterious effects of senescence within the tissue.

TGFβ, a cytokine involved in proliferation, migration, cellular differentiation and cell cycle regulation, is a critical element for the establishment of paracrine senescence through the SASP. TGFβ induces and maintains paracrine senescence through a mechanism that generates reactive oxygen species and DDR. And by inducing p21 expression in a p53 independent manner through the regulation of p27 and p15.

However, despite a number of studies suggesting a potential link between senescence and biliary disease, it has not been shown whether senescence is actually a driver of the damage rather than solely a consequence. We have therefore investigated the relationship between senescence and biliary disease, focusing on SASP-related mechanisms to explain part of the pathophysiology of PSC/PBC.

Here, we present a model of biliary disease, based on the conditional deletion of Mdm2 in bile ducts under the control of the Krt19 cholangiocyte promoter. In this model, senescent cholangiocytes induce profound alterations in the cellular and signalling microenvironment, with recruitment of myofibroblasts and macrophages causing collagen deposition, TGFβ production and induction of senescence in surrounding cholangiocytes and hepatocytes. Finally, we study how inhibition of TGFβ-signalling disrupts the transmission of senescence and restores liver function. In doing so we provide potential opportunities for therapies based on the disruption of the TGFβ-dependent SASP response.

Results
Cellular senescence is an intrinsic feature of PSC/PBC. Assessment of PSC/PBC human biopsies corroborate the presence of previously described senescence-factors like p21 (Fig. 1a). p21 is also expressed in some perportal hepatocytes (Fig. 1a).

Other senescence markers such as p16 (Fig. 1b), DCR2 (Fig. 1c), γH2A.X (Fig. 1d) and p27 (Fig. 1e) are also present in Keratin 19 (K19)-expressing cholangiocytes. Again, some perportal hepatocytes express markers of senescence such as γH2A.X and DCR2 (Supplementary Fig. 1a, b).

PSC and PBC are clinically characterized by increased ductular response (Supplementary Fig. 1c), apoptotic bile ducts (Supplementary Fig. 1d), extensive fibrotic areas (Supplementary Fig. 1e) and copper deposition (Supplementary Fig. 1f), all important factors for the evolution of the disease.

Deletion of Mdm2 results in p21-driven senescence. To test whether senescence could be a pathological driver of such cholangiopathies, we developed a model in which biliary senescence is triggered in cholangiocytes using a tamoxifen-inducible K19-Mdm2^fl/fox^tdTom^LSL^ mice (Fig. 2a).

Murine Double Minute 2 (Mdm2) is a key negative regulator of p53, that positively regulates p21 expression. Therefore, cholangiocyte-specific (via Keratin19CreER<sup>T2</sup>) deletion of Mdm2 results in p21 expression in bile ducts (Fig. 2b and Supplementary Fig. 2a, b).

Low occurrence of proliferating p53-positive cholangiocytes (0.1% Mean ± SEM) (Fig. 2c and Supplementary Fig. 2c) suggests that activation of the p53-p21 axis initiates cell cycle arrest. Expression of other senescence markers like 53BP1, γH2A.X and DCR2 (Fig. 2d) suggests the occurrence of cellular senescence in cholangiocytes. Furthermore, some hepatocytes also express 53BP1, γH2A.X and DCR2 (Fig. 2d) while maintaining Mdm2 expression (Supplementary Fig. 2d). This suggests that the presence of senescent hepatocytes is a consequence of paracrine activity from the cholangiocytes and not due to Cre-recombination or spontaneous loss of Mdm2 in hepatocytes.

Cre activity in senescent cholangiocytes can be traced by the expression of tdTomato (tdTom) (Fig. 2e), which is restricted to cholangiocytes indicating that Cre activity is cholangiocyte specific. The percentage of recombined tdTom-positive cells that proliferate is very low and does not significantly vary over the course of 90 days, suggesting that the cell cycle arrest remains unaltered (Supplementary Fig. 2e). Furthermore, tdTom expression colocalizes with p53 in cholangiocytes (Fig. 2f), suggesting that p53 expression is directly associated with tdTom presence in cholangiocytes.

The percentage of tdTom-positive cells remain unchanged in the liver 90 days post-induction (Supplementary Fig. 3a), accompanied by ductular reaction (Supplementary Fig. 3b, c). Over the course of 90 days, we observed liver disease progression as evidenced by changes in liver biochemistry, including alanine aminotransferase, aspartate aminotransferase and bilirubin (Supplementary Fig. 3a). We did not observe ductopenia (Supplementary Fig. 3c).

Our model also displays p16 in cholangiocytes and some hepatocytes (Supplementary Fig. 4a), suggesting that senescence expands from cholangiocytes towards the parenchyma through paracrine signalling.

Furthermore, K19-Mdm2<sup>fox/fox</sup>tdTom<sup>LSL</sup> mice display large mononuclear infiltrates (Supplementary Fig. 4b) which were identified as F4/80-positive macrophages (Supplementary Fig. 4c), suggesting the presence of cholangiocyte-dependent paracrine signalling. Twenty-one days after induction, apoptosis occurs in the bile ducts (Supplementary Fig. 4d), which was previously described in human PSC/PBC and could potentially amplify the effect of senescence to exacerbate biliary injury.

We found increased intensity of αSMA-positive cells surrounding the senescent cholangiocytes (Fig. 2g, h and Supplementary Fig. 5a, b, c). We also found increased collagen deposition (Fig. 2i) that progressively accumulates over the course of 90 days (Supplementary Fig. 5d).

As our model induces cellular senescence in the K19-positive epithelia, we examined other organs (kidney and gut) for markers of cellular senescence such as p16 (Supplementary Fig. 6a). Both kidney and gut presented increased levels of fibrosis over the course of 90 days (Supplementary Fig. 6b). We did not find evidence of the involvement of mesothelial cells in our model (Supplementary Fig. 6c).

We also compared the senescence response in Mdm2<sup>fox/fox</sup> models with different promoters (see Supplementary Fig. 7a for K19-Mdm2<sup>fox/fox</sup>tdTom<sup>LSL</sup> model, and Supplementary Fig. 7b for OPN-Mdm2<sup>fox/fox</sup>YFP, respectively), both targeting cholangiocytes. Both models present similar levels of recombination (Supplementary Fig. 7c) and induction of senescence in...
Fig. 1. Cellular senescence is an intrinsic characteristic of PBC/PSC. Explanted human livers diagnosed as Normal, PSC and PBC respectively (series of N = 7 per group). a Immunohistochemical detection of p21 in bile ducts. Far right, digital magnification of p21-positive hepatocytes (top) and cholangiocytes (bottom). b PSC and PBC show p16 expression (red) in cholangiocytes (green). Far right, quantification of p16 in K19-positive cholangiocytes. Median age of each of the groups is also included in this figure. c PSC and PBC show DCR2 expression (green) in cholangiocytes (red). Far right, quantification. d PSC and PBC show γH2A.X expression (green) in cholangiocytes (red). Far right, quantification. e Immunohistochemical detection of p27 increases in PSC and PBC compared to Normal Liver. ** denotes p < 0.01, *** denotes p < 0.001, **** denotes p < 0.0001 (Mean ± SEM). ANOVA, Sidak’s multiple comparisons test. Scale bars = 50 µm.
Fig. 2 Cholangiocyte-specific deletion of Mdm2 results in p21-driven cellular senescence. **A** Schematic explanation of the model: K19CreER\(^T\) promoter is used to flox out Mdm2 in cholangiocytes. Upon tamoxifen administration, Cre recombinase is activated and Mdm2 is cleaved. The STOP sequence upstream tdTom reporter sequence is also floxed out making the identification of primary senescent events traceable through tdTom expression. **B** Increased levels of p21 in bile ducts 2 days after tamoxifen administration. Mouse data is presented at day 2 after final tamoxifen administration (\(N=6\) per group). (Left) K19Cre-positive mice without tamoxifen injection. (Center) K19Cre-negative mice after tamoxifen injection. (Right) K19Cre-positive mice after tamoxifen injection. **C** Cell-cycle-arrested cells do not proliferate. 0.1% (Mean ± SEM) of cholangiocytes co-express p53 (red) and Ki67 (green) 2 days after tamoxifen administration. **D** From top to bottom: 53BP1, \(\gamma\)H2A.X-positive and DCR2-positive hepatocytes in Cre+ +TM group. Bottom panel: Cre− +TM shows some DCR-positive hepatocytes (white arrowheads). **E** Recombined K19-positive cholangiocytes (green) can be traced by means of tdTom expression (red). **F** tdTom (red) co-localizes with p53 (green) in bile ducts. **G** Increased intensity of \(\alpha\)SMA-positive cells (green) contiguous to tdTom-positive senescent-cholangiocytes (red) compared with tdTom-negative bile ducts at day 21 after induction \(N=6\). For an explanation about how this result was acquired, refer to Supplementary Fig. 5. **H** Increased total percentage of \(\alpha\)SMA-positive cells in the Cre+ +TM group at day 21. **I** Increased deposition of collagen measured by PicroSirius Red (PiSR) at 21 days after tamoxifen induction. Right, quantification. ** denotes \(p < 0.01\) (Mean ± SEM), Student’s ttest. Scale bars = 50 \(\mu\)m.
Fig. 3 Paracrine senescence in the model is TGFβ-dependent. Mouse data is presented at day 2 after final tamoxifen administration (N = 6 per group). (Left) K19Cre-positive mice without tamoxifen injection. (Center) K19Cre-negative mice after tamoxifen injection. (Right) K19Cre-positive mice after tamoxifen injection. a p53 (red, indicative of primary senescence events in the cholangiocytes) and p21 (green) co-localize in the bile ducts. However, p21-positive p53-negative cholangiocytes were observed. b p21 (green) co-localizes with HNF4α-positive hepatocytes (red). c p27 (green) colocalizes with p53-positive cholangiocytes (red). p27 is expressed in cholangiocytes and hepatocytes in a paracrine manner. d p27 (green) co-localizes with HNF4α-positive hepatocytes (red). e Markers of senescence (such as 53BP1, H2A.X and DCR2, in red) are expressed in cholangiocytes and liver parenchyma, while expression of p53 (green) is restricted to the cholangiocytes. Single channels for this figure are provided in Supplementary Fig. 8a. Scale bars = 50 µm. f qRT-PCR analysis of Tgfb1 in the isolated bile ducts of Cre− + TM (N = 5) and induced Cre+ + TM (N = 6) K19-Mdm2flox/flxtdTomLSL mice day 2 after induction. *** denotes p < 0.005 (Mean ± SEM). Mann–Whitney test. g Analysis of common SASP’s factors by qRT-PCR (from left to right, Tgfbr1, Tgfbr2, Nfkb, Il1a and Il6). * denotes p < 0.05, ** p < 0.01 (Mean ± SEM). Mann–Whitney test. h Western blot of phospho-NF-κB-p65 and pSmad2/3. Each band represents the bile ducts isolated from one mouse. Blots are companied by at least one marker position (molecular weights MW, in kDa). Far right, western blot densitometry quantification (normalized to bActin control) show increased expression of NF-κB-p65 and pSmad2/3 after induction of the model. * denotes p < 0.05 (Mean ± SEM). Mann–Whitney test. i qRT-PCR of Nfkb in hepatocytes isolated from Cre− and Cre+ K19-Mdm2flox/flxtdTomLSL mice at day 2 after last tamoxifen administration (N = 5-6 per group). ** denotes p < 0.01 (Mean ± SEM). Mann–Whitney test.
cholangiocytes (Supplementary Fig. 7d). Furthermore, while expression of the tdTom or YFP is restricted to cholangiocytes, scattered expression of p21 can be seen in the parenchyma (Supplementary Fig. 7e), suggesting that there is a mechanism that induces senescence in a paracrine manner. Furthermore, we found p21-positive, p53-negative cholangiocytes (Supplementary Fig. 7f) in both models, suggesting a non-autonomous activation of p21, independent of the activation of p53 after Cre recombination. Altogether, these results partially resemble the main characteristics of clinical PSC/PBC\(^1\)–\(^3\) and suggest that senescent cholangiocytes generate a local microenvironment that induces paracrine senescence in the surrounding hepatocytes, promotes macrophages recruitment and induces collagen deposition.

**Paracrine senescence in the model is TGFβ-dependent.** Following Cre activation, p21-positive, p53-negative cholangiocytes were observed in bile ducts (Fig. 3a). Furthermore, while p53 expression is restricted to cholangiocytes (Fig. 3a), we detected p21-positive HNF4α-positive hepatocytes (Fig. 3b). p27, a direct target of transforming growth factor β (TGFβ) \(^{11,19-21}\), is also expressed in cholangiocytes and hepatocytes in a similar pattern to p21 (Fig. 3c, d).

These senescent hepatocytes also express other senescence markers (53BP1, γH2A.X and DCR2), while p53 is restricted to the bile ducts (Fig. 3e and Supplementary Fig. 8a and b). These observations indicate that senescence triggered in hepatocytes is non-autonomous and p53-independent. This suggests the
Increased expression of Tgfbr1 (p16) (Supplementary Fig. 9b).

Furthermore, bile ducts from induced mice present significant increases in Ki67 (green) in the S+PH group in comparison with PH group and Sham at 48 h post PH. Far right, quantification of total proliferation in the liver. *p < 0.05, **p < 0.0001, (Mean ± SEM). ANOVA, Sidak’s multiple comparisons test. Scale bars = 50 μm.

Fig. 5 Cellular senescence in cholangiocytes impairs the regenerative response of liver parenchyma. a Schematic representation of the experiment. After induction of the model, we waited 2 days for display of senescence and performed 70% PH. Livers were recovered at day 2 after the surgery (peak of DNA replication in hepatocytes) and day 7 (when the liver mass is restored). Two groups were included in this experiment; PH (N = 8) and Senescence + PH (S + PH, N = 7). Sham animals are included as controls of the PH technique (N = 4). b Whole livers collected at 48 h post PH. From left to right: Sham (no manipulation of the liver), PH (which shows normal regenerative process by compensatory hypertrophy) and S+PH. Notice the absence of compensatory hypertrophy in the S+PH liver.

We observed upregulation of Nfkb (p = 0.0132) and Il1a (p = 0.0160) while there is a trend to increase in Il6 level (p = 0.1708) (Fig. 3g and Supplementary Fig. 9c).

Western blot analysis also revealed increased protein levels of pSmad2/3, suggesting a direct functional role for TGFβ in the activation of the SMAD complex (Fig. 3h).

Increased levels of phospho-NF-κB-p65, a master regulator of the SASP, at protein (Fig. 3h) and gene level (see Fig. 3g) suggest a robust activation of the SASP in bile ducts. Interestingly, we observed upregulation of Nfkβ in hepatocytes after Cre activation (p = 0.0010) (Fig. 3i). Isolated hepatocytes also significantly upregulate Tgfb1 (p = 0.0043) and Tgfb2 (p = 0.0173) (Supplementary Fig. 9d).

We observed upregulation of Nfkβ in hepatocytes after Cre activation (p = 0.0010) (Fig. 3i). Isolated hepatocytes also significantly upregulate Tgfb1 (p = 0.0043) and Tgfb2 (p = 0.0173) (Supplementary Fig. 9d).

Furthermore, in situ hybridization (ISH) for Tgfb1-ligand also suggests that TGFβ is produced by cholangiocytes and surrounding hepatocytes (Supplementary Fig. 9e). These results suggest a potential mechanism of paracrine senescence activation triggered by the SASP in the parenchyma.

The above observations indicate that the K19-Mdm2lox/loxtdTomLSL model robustly establishes senescence in cholangiocytes and induces a TGFβ-dependent SASP response in the parenchyma.
Cellular senescence aggravates biliary injury. To test if cholangiocyte senescence affects the outcome of biliary injury, we administered 1 week of diethoxycarbonyl-1,4-dihydro-collidine (DDC) diet to the K19-Mdm2$^{lox/lox}$dTom$^{LSL}$ model (Fig. 4a). The DDC diet has been previously used to induce features of PSC/PBC but, up to date, the effects of senescence in this model are not known.

Following DDC administration, there is a significant increase of serum transaminases in the tamoxifen-injected group (Fig. 4b). Decrease in cholangiocyte proliferation (Fig. 4c) and increased p21-positive cholangiocytes (Fig. 4d) can be observed in concurrence with decreased total liver proliferation (Fig. 4e). Increased number of p21-positive hepatocytes (Fig. 4f) and p27-expressing cells can be seen in the tamoxifen-injected group.
(Fig. 4g), supporting the hypothesis that senescence spreads from cholangiocytes to the rest of the liver. Further comparison between control groups (healthy wild-type mice, wild-type mice on DDC diet and the uninduced K19-Mdm2fl/fl;tdTom1LSL model) can be found in Supplementary Fig. 10a-e.

Furthermore, increased aSMA-positive cells proximal to tdTom-positive cholangiocytes (Fig. 4h) and collagen deposition (Fig. 4i) suggest that senescent cells generate a local microenvironment that results in fibrogenesis. Increased number of F4/80-positive macrophages (Fig. 4j) can also be observed in the tamoxifen-injected group. We did not find significant differences in the total number of K19-positive cells between the vehicle and tamoxifen-injected group after DDC diet (Supplementary Fig. 10).

These data altogether suggest that senescence can aggravate biliary injury by spreading to the parenchyma.

**Cellular senescence impairs liver parenchyma regeneration.** To test whether the effects of paracrine senescence upon the hepatocytes affect the regenerative capacity of the liver, we induced senescence in cholangiocytes in the K19-Mdm2fl/fl;tdTom1LSL model and tested hepatocyte regenerative capacity with 70% partial hepatectomy (PH), a well-described model of hepatocyte regeneration (Fig. 5a). Decreased proliferation (Fig. 5c and Supplementary Fig. 11a) and increased p21-positive hepatocytes (Fig. 5d and Supplementary Fig. 11b) occur in the senescent group. We observed increased p27 expression (Fig. 5e) suggesting an active role of TGFβ-dependent SASP mechanism in the parenchyma.

One week after PH there was a marked decrease in survival in the senescent group (Fig. 5f), suggesting that the livers subjected to cholangiocyte senescence and SASP effects are unable to compensate the loss of liver tissue. We did not find evidence of the involvement of mesothelial cells in our model (Supplementary Fig. 11d).

These results suggest that cholangiocyte senescence impairs the regenerative response of the liver parenchyma. This could potentially account for the loss of hepatocyte function seen in human PSC/PBC patients.

**Senescence is transmitted in vitro through TGFβ.** To test whether transmission of senescence from cholangiocytes to the surrounding hepatocytes is TGFβ-dependent, we generated an in vitro model based on the induction of paracrine senescence in culture expanded biliary cells derived from normal mouse liver as previously described.

As previously shown by Tabibian and collaborators, N-Ras activation is an intrinsic characteristic of senescent cholangiocytes in PSC. We generated a system of paracrine senescence based upon N-RAS activation (Fig. 6). Briefly, we added conditioned media from senescent cells (CM-SASP) to our biliary cells (Fig. 6a). CM-SASP is produced by IMR90 ER:RAS cells in which senescence is induced by means of the activation of a RAS-chimaeric fusion protein.

CM-SASP induced senescence in the biliary cells, causing growth arrest (Fig. 6b), with increased miRNA levels of cdkn1a, cdkn1b and cdkn2a (Fig. 6c). Altered cell morphology (Fig. 6d) and upregulated expression of several senescence markers with reduced BrdU incorporation (Fig. 6e, f) are observed.

With the same method, we induced senescence in biliary cells, withdrew the CM and then added YFP-positive biliary cells (Fig. 7a). This allows the assessment of the paracrine senescence transmission from the senescent biliary cells to the YFP-biliary cells. Quantifications in the YFP-biliary cells showed increased senescent markers and decreased BrdU incorporation, demonstrating that senescence can be transmitted in a paracrine manner (Fig. 7b).

In order to inhibit the transmission of paracrine senescence, we blocked TGFβ signalling pathway and assessed the same markers of senescence in the YFP-biliary cells. To that purpose, we used a small molecule that targets the TGFβ receptors ALK4, ALK5 and ALK7 (LY2157299), effectively blocking TGFβ signalling pathway (Fig. 7c).

Addition of LY2157299 caused a significant reduction of paracrine senescence in the YFP-biliary cells (Fig. 7d and Supplementary Fig. 12a, b), without altering the number of primary senescent biliary cells (Supplementary Fig. 12c). These results accentuate the importance of TGFβ in the transmission of paracrine senescence, and offers a potential approach for the inhibition of paracrine senescence in biliary disease.

Finally, we investigated whether macrophages are able to clear senescent biliary cells. We established an in vitro system in which senescent YFP-biliary cells were co-cultured with bone marrow-derived macrophages artificially labelled with 647-Cell Mask (647-BMDM). Interaction between the senescent YFP-biliary cells and 647-BMDM can be observed in the co-culture system (Supplementary Fig. 13a-h). The number of senescent biliary cells significantly decreased after 72 h when cultured with 647-BMDM (Supplementary Fig. 13b), suggesting that BMDMs can target and eliminate senescent biliary cells.

**Inhibition of TGFβ in vivo improves liver function.** We investigated the therapeutic effect of TGFβ signalling disruption during paracrine senescence in the DDC biliary disease model. LY2157299 treatment (Fig. 8a) resulted in decreased number of p21-positive cholangiocytes (Fig. 8b, c), a significant reduction of total p21 (Fig. 8d) and p27-expressing cells in the liver (Fig. 8e), reflecting a decrease in the paracrine senescence response. The number of primary senescent cholangiocytes (tdTom-positive) remain unaltered (Fig. 8f), proving that primary senescence is not affected by the administration of LY2157299.

Administration of LY2157299 in the K19-Mdm2fl/fl;tdTom1LSL model prior to DDC diet (Fig. 8g) resulted in improved liver function as shown by decreased serum transaminases.
(Fig. 8h), increased number of proliferating cholangiocytes (Fig. 8i) and increased liver proliferation (Fig. 8j). These results correlate with a trend towards decrease in p27-positive cells ($p = 0.0952$; Fig. 8k), and reduced p21-positive and p16-positive hepatocytes (Fig. 8l). We also observed a decrease in collagen deposition (Fig. 8m) that may reflect a decrease in the fibrogenic response, and a trend towards decreased numbers of F4/80 macrophages ($p = 0.1508$; Fig. 8n).

**Discussion**

Cellular senescence is the permanent cell-cycle arrest related to the process of ageing and has recently been described as a

![Diagram](image_url)
tumour-preventive mechanism. In the liver, it has been associated with cholangiocytes in end-stage liver disease, identified in hepatocytes in cirrhotic livers and described as a mechanism to control hepatic stellate cell-mediated fibrogenesis.

In biliary disease, senescence has proved to be an essential characteristic of PSC/PBC. Sasaki et al. described the presence of senescent cells in human PSC/PBC, and Tabibian et al. suggested the importance of N-Ras-induced senescence and its paracrine effects in PBC. Furthermore, the Mdr2 knock-out mouse model exhibits high levels of p16-dependent cholangiocyte senescence, and is characterized by the spontaneous development of cholangitis and 'onion skin' periductal fibrosis, suggesting a potential contribution of senescence to the development of biliary disease. These observations highlight the importance of cholangiocyte-senescence in biliary disease.

We have developed a highly efficient model to induce senescence specifically in cholangiocytes, partially resembling human biliary disease. This model offers the advantages of conditional activation and can be used as a tool to study the mechanisms of biliary senescence in the liver. The presence of senescent cholangiocytes in this model promotes ductular reaction, increases deposition of collagen and impairs liver regeneration after injury. The presence of αSMA-positive cells in the proximities of the senescent cholangiocytes suggests that senescence might have a role in the development of fibrosis, characteristic of human PSC/PBC.

After induction, our model exhibits biliary duct apoptosis. This suggests that biliary senescence generates an environment permissive for the initiation of apoptotic mechanisms (previously described as a potential mediator of ductopenia), but further investigations are required to investigate the mechanisms behind this phenomenon.

The presence of senescent cholangiocytes aggravates biliary disease upon administration of DDC diet and confirms that senescent cholangiocytes exert a detrimental role in the development of biliary disease and regeneration. Senescent cholangiocytes affect their microenvironment, altering macropheage infiltration, collagen deposition and impairing biliary functions. The induction of senescence in cholangiocytes also results in the establishment of paracrine senescence in the liver parenchyma through TGFβ-dependent mechanisms. This suggests that the initial wave of senescence in the bile ducts might spread and compromise the regenerative ability of the liver parenchyma, confirmed by the decreased survival of animals subjected to biliary senescence and 70% PH.

As a role for senescent cholangiocytes in the attraction of macrophages has been suggested in PBC, we used an in vitro model to investigate the interaction between macrophage infiltration and senescent cholangiocytes observed in the in vivo model. The number of senescent cholangiocytes decreases when co-cultured with BMDM, suggesting that macrophages can target and eliminate senescent cholangiocytes. These observations provide a potential mechanism that explains the disappearance of bile ducts seen in human PSC/PBC.

Architecture is not present in this model; however, ductopenia is a late feature in PSC/PBC and likely occurs over years of injury and impaired regeneration, which is challenging to simulate in a mouse model.

Inhibition of TGFβ signalling partially blocks paracrine senescence effects. Consistently, we have demonstrated that in vivo partial ablation of the SASP through TGFβ inhibition decreases paracrine senescence, increases hepatocyte proliferation and liver function. Furthermore, it appears to decrease fibrogenesis in our model (although it should be noted that TGFβ inhibition can also decrease liver fibrosis). We suggest that senescence may contribute to the development of biliary disease through complementary mechanisms. First, through an impaired regenerative response of cholangiocytes, unable to compensate biliary damage, and second, through SASP expression, that can induce paracrine senescence in hepatocytes (thus diminishing the regenerative capacity of the liver during injury).

Overall, we have shown that cellular senescence is likely to be a driver of biliary injury by affecting the microenvironment, impairing liver parenchyma regeneration and impairing biliary function. Importantly, we have found that this pathology can be specifically targeted through TGFβ inhibition.

Methods

Clinical material. Human liver biopsies from a clinical series of PSC and PBC cases (paraffin-embedded samples, n = 7 per group) were anonymized and assessed histologically using H&E by an expert pathologist. Diagnoses were based on clinical data and confirmed by histology (see Supplementary Table 1). Normal human liver samples were obtained from autopsy cases from non-hepatic disease with normal liver histology (n = 7). Informed consent was obtained from the patients for the tissue to be used in the Tissue Governance Group, College of Medicine and Veterinary NHS Lothian Public Health Office, under project license TGU-LAB-SR299 approved by the Local Commission for Medical Ethics, University of Edinburgh.

Animal models. Mice were housed in a specific pathogen-free environment in open cages (NKP, M3-sloping front) with Aspen chips as bedding at 21 °C. Mice were kept under standard conditions with a 14-h day cycle and access to food (irradiated RM3P) and water ad libitum. Power calculations are not routinely performed. However, animal numbers were chosen to reflect the expected magnitude of response taking into account the variability observed in previous experiments. Mice were randomly allocated to each experimental group and males/females are equally distributed. All animal experiments were carried out under procedural guidelines, severity protocols and within the UK with ethical permission from the Animal Welfare and Ethical Review Body (AWERB) and the Home Office (UK).

K19CreER7.5 and K19CreERT2.5 mice were crossed with Mdm2lox/lox and R26RdTomatoSL mice to generate K19-Mdm2lox/loxRdTomatoSL mice. Normal liver samples were obtained from K19CreERT2.5+/− and K19CreERT2.5−/− mice (Cre− and Cre−, respectively), and K19CreERT2.5+/− mice under 1 week of DDC diet were also included as control of the DDC diet in our model. OPNiCreERT2.5+ and OPNiCreERT2.5− mice were crossed with Mdm2lox/lox and R26RdTomatoSL mice to generate OPN-Mdm2lox/loxRdTomatoSL mice (Cre+ and Cre−). The animals used on this study have CD1-enriched background, mix of males and females aged within 8–12 weeks at the start of the experiments.

C57Bl/6 mice were used in some figures (see as example Supplementary Fig. 10) as healthy control. C57Bl/6 mice aged within 8–12 weeks at the start of the experiments. C57Bl/6 mice were used in some figures (see as example Supplementary Fig. 10) as healthy control. C57Bl/6 mice aged within 8–12 weeks at the start of the experiments.

K19CreER7.5 and R26RdTomatoSL mice were purchased from Jackson Laboratory.
OPNiCreERT2R26RYFP mouse line was a kind gift by F. Lemaigre and I. Leclercq, Institut de Recherche Expérimentale et Clinique and Duve Institute Brussels, Belgium. Mdm2fl/flox/fo mice were generously provided by Professor Gigi Lozano, Department of Cancer Genetics, University of Texas. All animal genotyping was outsourced commercially to Transnetyx, Inc (TN, USA) using the primers stated in Supplementary Table 2.

Further details (ARRIVE guidelines) about the use of the animal models can be found in Supplementary Note 1.

**Induction of the model and recovery of samples.** Recombination of loxP sites was induced with three doses of 4 mg tamoxifen (Sigma) in sunflower seed oil (Sigma) by intraperitoneal injection on alternate days. Mice were killed according to UK Home Office regulations and blood collected by cardiac puncture and centrifuged to collect serum. Livers were perfused in situ with PBS through the portal vein and harvested. Organs were harvested and either directly frozen at −80 °C or fixed in 10% formalin (in PBS) for 12 h prior to embedding in paraffin blocks.

**DDC diet.** To induce biliary injury, mice were given 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) mixed with Rat & Mouse No Maintenance (RM1) diet (Special Diet Services) as previously described39. DDC diet was administered for 7 days, 2 days after last tamoxifen injection. Although the literature describes prolonged periods of DDC feeding in different mouse models, the K19-Mdm2flox/floxtdtomLSL mice

### Table

<table>
<thead>
<tr>
<th>Day</th>
<th>% Ki67/K19</th>
<th>% p21/Krt19</th>
<th>% p16</th>
<th>% PSR</th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>0.8</td>
<td>0.5</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Veh</td>
<td>1.0</td>
<td>0.2</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>DDC</td>
<td>0.6</td>
<td>0.1</td>
<td>0.5</td>
<td>0.5</td>
</tr>
</tbody>
</table>

* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

**Figure Legends:**

- **a:** K19-Mdm2flox/floxtdTomLSL mice
- **b:** Vehicle, 10 mg/kg, 20 mg/kg
- **c:** % p21/Krt19
- **d:** % p21
- **e:** % p27
- **f:** % TdTom/Krt19
- **g:** K19-Mdm2flox/floxtdTomLSL mice
- **h:** ALT u/l, Cholest mmol/l, Bilirubin umol/l
- **i:** Vehicle, Isotype, S+Veh+DDC, S+Inh+DDC
- **j:** % Ki67/K19, % Ki67
- **k:** % p27
- **l:** % p16
- **m:** Vehicle, Isotype, S+Veh+DDC, S+Inh+DDC
- **n:** % PSR, % F4/80

* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

**Notes:**

- [Supplementary Table 2](#)
- [Supplementary Note 1](#)
- [ARRIVE guidelines](#)
70% partial hepatectomy. Briefly, median laparotomy was performed under isoflurane anaesthesia and left lateral and median lobe were removed as previously described18. To avoid damaging the gallbladder, the ‘three knots’ technique was performed. Sham-operated mice were subject to laparotomy and brief manipulation of the intestines, but no hepatectomy was performed. Mice were killed at 48 h and 1 week after surgery.

In vivo use of TGFβ1/1 antagonists. Galunisertib (LY2157299, Cayman Chemical Company) was administered at 10 mg/kg twice daily by gavage after the induction of the model until day 2, when we administered DDC diet as stated. LY2157299 was prepared in 10% polyethylene glycol, 5% DMSO and 85% saline vehicle. Control mice were administered only with the vehicle (PEG, DMSO, Saline).

Serum analysis. Serum analysis used commercial kits according to the manufacturer’s instructions; serum albumin (Alb), bilirubin and alanine transaminase (ALT) (Alpha Laboratories); aspartate aminotransferase (AST) and alkaline phosphatase(ALP) (Randox laboratories); Cholesterol (Wako Chemicals GmbH). All kits were adapted for use for a Cobas Faro centrifugal analyser (Roche Diagnostics).

Histology. Paraflin sections (4 μm) were cut and stained. Antibodies used for antigen detection in the current study are provided together with method of antigen retrieval, working dilution and isotype control (Supplementary Table 3).

Immunohistochemistry. For tissue, 100 mM sodium citrate pH 6.0 or 100 mM Tris-EDTA pH 9.0 were used for antigen retrieval. Sections were blocked for endogenous peroxidase and alkaline phosphatase activity (Bloxall, Vector), endogenous avidin/biotin (Invitrogen) and nonspecific protein binding (Spring Bioscience). Primary antibodies were incubated as stated in Supplementary Table 3. Species-specific secondary biotinylated antibodies (Vector), Vectastain R.T.U, ABC reagent (Vector) and DAB chromogen (Dako) were used sequentially to detect the primary antibody. Sections were counterstained with haematoxylin.

Isotype control is used in the same concentration as the primary antibody. The sample is then incubated with the secondary antibody and detection reagents.

Immunofluorescence. For tissue, 100 mM sodium citrate pH 6.0 or 100 mM Tris-EDTA pH 9.0 were used for antigen retrieval. Sections were blocked with protein block (Spring Bioscience) and incubated using antibodies listed in Supplementary Table 3. Primary antibodies were detected using fluorescent-conjugated secondary antibodies (Alexa-488, 555 of 650, Invitrogen). Sections were mounted with DAPI containing media (DAPI Fluoromount-G, SouthernBiotech).

Isotype control is used in the same concentration as the primary antibody. The sample is then incubated with the secondary antibody and detection reagents.

TUNEL. Apoptosis was assessed using In Situ Cell Death Detection Kit (Roche) according to the manufacturer’s instructions. Positive control was performed using 10 units/ml of DNaseI (Quagen).

Haematoxylin and eosin. Sections were stained routinely and mounted in fluorescence-free DPX mountant (Sigma).

PicroSirius Red. Sections were stained using picric acid (P7641-1GA), fast green (F7258-2SG) and direct red (365548-25G, all from Sigma Aldrich).

In situ hybridization. In situ mRNA hybridization (ISH) was performed using RNAscope LS probes for Tgfl1, Mdm2 and PPIB control (407758, 447668 and 313918; Advanced Cell Diagnostics) as per the manufacturer’s instructions. Images were acquired and each probe was quantified in cholangiocytes and hepatocytes, which are identified based on their morphology.

In vitro studies. Biliary cells were obtained as previously described and routinely used in our laboratory29,40. YFP-Biliary cells is a stably transfected GFP biliary cell line derived in the laboratory29. Prior use in our experiments, YFP-Biliary cells were cultured with medium supplemented with 3 μg/ml of puromycin (Thermo Fisher) for 14 days to exclude cells that randomly lose YFP. YFP expression of stably transfected lines was constantly monitored with fluorescence microscopy.

Biliary cells are cultured in Williams’ E 10% FCS supplemented with 20 mM HEPES pH 7.5, 17.6 mM NaHCO3, 10 mM nicotinamide, 1 mM sodium pyruvate, 1x ITS, 100 mM dexamethasone, 0.2 mM ascorbic acid, 14 mM glucose 1.4 μl, 10 ng/ml IL-6 10 μg/ml, 10 ng/ml HGF 20 μg/ml, 10 mg/ml EGF 100 μg/ml as previously described40. All experiments were performed at passage 16–17.

Induction of senescence with conditioned medium. To induce senescence, we treated biliary cells with conditioned media for a week. For co-culture experiments, cells were counted, conditioned media eliminated and cells washed with PBS1x five times before plating same number of YFP-Biliary cells. For the inhibition of TGFβ signalling experiment, LY2157299 (Cayman Chemical Company) solubilized in DMSO was added at the stated concentrations. DMSO was used for controls. Conditioned media-SASP (CM-SASP) was produced as described in Acosta et al.32. Briefly, IMR90 ER:RAS cells (2×10^6) were seeded in a 10 cm dish and incubated for 7 days with 200 mM 4OHT in DMEM with 0.5% FBS. After incubation, the conditioned medium (CM) was collected, centrifuged at 5000 × g and filtered through a 0.2 μm pore filter. CM was mixed with DMEM 49%, FBS in a proportion of 3 to 1 to generate CM containing 10% FBS. Control conditioned media (CM-Ctrl) is produced in the same manner from IMR90 ER:RAS cell line.

DDAOG detection of SA β-Galactosidase activity. Cells were sequentially cultured with 100 mM Bafloymcin A1 (Sigma) and 100 μM DDAOG (Thermo), 1 and 2 h respectively at 37 °C as previously described9. Cells were then fixed 15 min 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 for 10 min. Images were acquired the same day at 647 nM exposure.

5-Bromo-2′-deoxyuridine incorporation. 5-Bromo-2′-deoxyuridine (BrdU) (Invitrogen) is added to the cells at 3 μg/ml and cultured 3 h at 37 °C. Cells were fixed in cold Methanol:Acetone (1:1) for 10 min and treated with 2 μl HCl 30 min at RT. Immunofluorescence was routinely performed (Supplementary Table 3).

Nuclear staining was performed with DAPI.

Immunofluorescence for cells. Cells were fixed in cold Methanol:Acetone (1:1) for 10 min and permeabilized with 0.1% Triton A-100 (Sigma) during 15 min before immunofluorescence was routinely performed. Antibodies used are listed in Supplementary Table 3. Nuclear staining was performed with DAPI.

Microscopy and cell counting. Images were acquired using a Nikon Eclipse e600 and a Hamamatsu C2900R camera (Q-imaging, Image Pro premier software) or Perkin Elmer Operetta high content imaging system. For single-cell quantification in tissue, images were acquired in up to four fluorescent channels at >x20 magnification, and analysed using Fiji Image or Columbus Image Data Storage and Analysis System (Perkin Elmer) software depending on the microscope used.

Histological sections were assigned a randomized blinded code prior to quantification by a separate researcher, and the randomization decoded at the time of the final data analysis. Quantification of different liver populations from the images was performed manually on 30 random non-overlapping fields per mouse (>x200 magnification).

Ductopenic index was calculated by dividing the number of K19-positive bile ducts per portal tract. Any ratio below a 0.5 threshold was considered ductopenia42.

Cells were identified based on DAPI stained-nuclei, morphology and specific staining for each population. Illumination correction and background.
normalization was performed using the sliding parabola module. For each experiment, identical thresholds were used in all images for assigning nuclei to a specific population.

For pixel analysis, ImageProPremier software was used to select regions of positivity and automatically analysed using a macro-instruction. Results are expressed as the mean ± standard error of positive pixels per field. PDR analysis used an AxioScan.Z1 (Zeiss) to acquire tiled images at ×20 magnification. Images were then analysed using a standard colour threshold in Fiji ImageJ.

DAPI, AlexaFluor 488, and 555 were detected using band paths of 415–480, 495–540 and 561–682 nm for 405, 488 543 nm lasers respectively. All scale bars denote 50 μm.

Isolation of hepatocytes. Mice were killed and their livers were perfused in situ with Liver Perfusion Medium (Gibco) and Liver Digest Medium (Gibco). The liver was then disrupted to yield a cell suspension, filtered through a 50 μm filter (BD Biosciences) and hepatocytes were pelleted by centrifugation at 135 × g for 1 min. Hepatocytes were then purified as previously described. Briefly, cells were underlayered with 1.06, 1.08 and 1.12 g/ml Percoll (Sigma) in PBS. The 1.08 mg/ml was spiked with phenol red to aid visualization. Cells were spun at 750 × g for 20 min. Fraction between the 1.08 and 1.12 mg/ml Percoll layers was harvested, purified again and transferred to Trizol (Life Technologies). Routinely, cells with hepatocyte morphology and expression of CYP2D6 (marker of hepatocellular differentiation) were obtained at over 99% purity.

Isolation of bile ducts. Bile duct isolation was performed as previously described. Spleen and livers were perfused with saline, dissected down to approximately 2–4 mm³ portions and covered with a mix of Collagenase-Dispase in 2% FCS Advanced DMEM/F12 (Thermo Fisher). This mix was incubated at 37 °C for 1 h and individual ductular structures were manually picked up, cleaned with 5% FCS DMEM (Thermo Fisher) and transferred to Trizol.

Isolation of BMDM and co-culture with senescent biliary cells. BMDM were isolated as previously described, and stained with 647-CellMask Deep Red Plasma membrane stain (ThermoFisher) following the manufacturer’s instructions. Biliary cells were treated with CM-SASP for 1 week and washed with PBS/fix five times. Number of cells were counted and the same ratio of pre-stained 647-BMDM was added. Both populations were cultured for 72 h.

Immunoblotting. Ductal structures were manually picked up, cleaned with 5% FCS DMEM and protein extracted with RIPA (Sigma) according to the manufacturer’s instructions. Protein content was quantified using a BSA standard and Pierce reagent before being resolved using SDS/PAGE and blotted onto nitrocellulose membrane. Membranes were blocked with 5% BSA on T-PBS during 1 h and re-incubated with the desired antibody overnight. All uncropped western blots can be found in Supplementary Figure 14.

RNA isolation followed by RT-qPCR and gene expression analysis. RNA was isolated from bile ducts and hepatocytes using Trizol (Life Technologies) and purified using RNease RNA extraction kit (Qiagen) according to the manufacturer’s instructions. RNA concentration and quality was assessed using a Nanodrop spectrophotometer (Thermo-Fisher). Reverse transcription was performed using Quantitec Reverse transcription kit (Qiagen). Real time-qPCR was performed on a LightCycler 480 II (Roche) with commercial primers from Qiagen’s Quantitec kit (stated in Supplementary Table 4). Each gene expression was assessed with its own standard curve and normalized using Peptidylprolyl Isomerase A (PPIA) as housekeeping gene. Samples were run in triplicate.

Statistical analysis. A minimum of four mice were included per experimental group. For cell culture exposure to bile, a minors ≥ 4 of independent biological replicates were performed.

Prism software version 5.0a (GraphPad Software, Inc) was used for all statistical analyses. Normal distribution of data was determined using D’Agostino and Pearson omnibus normality test with Welch’s correction if variances differed (F test). For parametric data, data significance was analysed using a two-tailed unpaired Student’s t-test. Non-parametric data was analysed using Mann–Whitney test. In cases where more than two groups were being compared, then a one-way ANOVA (with Bonferroni correction) was used. Survival curves are calculated using Log-Rank comparison (Mantel–Cox test) and Gehan–Breslow–Wilcoxon test.

Statistical significance was assumed at p < 0.05. Data is presented as mean ± standard error of the mean (SEM). N refers to biological replicates.

Data availability. The authors declare that all data supporting the findings of this study are available within the article and its supplementary information files or from the corresponding author upon reasonable request. No data sets were generated or analysed during the current study.

Received: 30 June 2017 Accepted: 1 February 2018

Published online: 09 March 2018

References


28. Mitchell, C. A. Reproducible and well-tolerated method for NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03299-5 | www.nature.com/naturecommunications


